Valued at USD 8.58 billion in 2019, the peptide based cancer therapeutics market is projected to reach USD 17.18 billion by 2027, growing at a CAGR of 9.1% during the forecast period 2020–2027. Growth is attributed to innovations in peptide based cancer treatment approaches, the growing prevalence of different cancer types, high-efficacy peptide drugs, and rising pharmaceutical interest in research and development. Peptide based drugs are also described as more cost effective, with higher efficacy and specificity and lower toxicity. North America is the largest revenue contributor.

Why Peptide Therapeutics Are Displacing Conventional Approaches

Conventional cancer therapeutics face manifold challenges. Lack of tumor selectivity, the risk of severe side effects, and growing drug resistance among patients have intensified the search for novel approaches. Peptide based cancer therapeutics have emerged as a feasible alternative on account of their low toxicity and high target selectivity. Pharmaceutical companies recognize the commercial potential of these peptides, and research efforts are expected to gain momentum during the assessment period.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market

Bortezomib Leads by Drug Type

By drug type, the market is categorized into Goserelin, Bortezomib, Leuprorelin, and others. In 2019, the Bortezomib segment accounted for the largest share, favored by higher drug sales, high efficacy, and low side effects. Bortezomib belongs to a class of medicines commonly known as proteasome inhibitors, indicated for multiple myeloma and lymphoma. Proteasome inhibitors work by blocking the action of proteasomes inside cells, which break down proteins in both cancerous and healthy cells.

Lung Cancer Dominates Cancer Type Segmentation

By cancer type, the report covers lung, breast, colorectal, prostate, skin, and stomach cancer. In 2019, lung cancer accounted for the majority of the share and is likely to maintain it over the study period. The high share is attributed to rising lung cancer cases across all age groups, with air pollution, occupational exposure to asbestos and silica, and smoking cited as primary causes. WHO statistics show lung cancer accounted for 1.8 million deaths globally in 2018.

The report also segments the market by mode of mechanism, covering inhibitory, necrosis-inducing, and pro-apoptotic peptides, and by distribution channel, covering hospital, retail, and online pharmacies. Geographically, the market spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with revenue presented in USD million for 2016–2027.

Regional Insights

North America is the largest revenue contributor, followed by Europe and Asia Pacific. Rising cancer incidence in the United States, with around 1,688,780 cancer cases recorded in 2017 according to the American Cancer Society and the National Center for Health Statistics, has accelerated demand for treatment solutions and intensified research. In Latin America, the Cancer Atlas identifies lung cancer as the leading cause of cancer death in the region, accounting for more than 75,300 deaths each year.

In Asia Pacific, rising disease prevalence in China, Japan, South Korea, and India is expected to boost research. China records more than 4.3 million new cancer patients each year, and WHO statistics cite 1.7 million lung cancer cases out of 8.9 million total cancer cases in 2015. Because conventional radiotherapies are significantly costlier, biotech companies are developing novel therapeutics. In Latin America, the American Cancer Society reports that more than 70 percent of cancers in Argentina and Brazil are diagnosed at an end stage. In India, WHO statistics for 2017 put the number of women suffering from cancer at 0.7 million.

Key Players in the Peptide Based Cancer Therapeutics Market

The peptide based cancer therapeutics includes both small and large players. Key companies include AstraZeneca PLC; Abbott; Allergan plc; Teva Pharmaceuticals; Pfizer Inc.; Takeda Pharmaceutical; Amgen, Inc.; Johnson & Johnson; AbbVie Inc.; and Valeant Pharmaceuticals Inc. The report's company list is not exhaustive.

More Trending Latest Reports By Polaris Market Research:

exploring-crucial-role-of-synoptophore-in-orthoptics-and-ophthalmology

https://www.polarismarketresearch.com/industry/agrochemicals-and-fertilizers

crop-protection-chemicals-market

polysilicon-market

tissue-paper-market

electronic-contract-manufacturing-services-market

malaysia-customer-experience-business-process-outsourcing-market

strategic-positioning-of-top-5-companies-in-oral-care-market-in-2025

us-industrial-cleaning-chemicals-market